pharmachologic effect

Antihypertensive agent. It is a specific antagonist of angiotensin II receptors. It has a selective antagonistic effect on AT1 receptors, which are responsible for the realization of the effects of angiotensin II.

Due to the blockade of AT1 receptors, the plasma concentration of angiotensin II increases, which can stimulate unblocked AT2 receptors. Has no agonistic activity against AT1 receptors. The affinity of valsartan for AT1 receptors is about 20,000 times higher than that of AT2 receptors.

Does not inhibit ACE. It does not interact and does not block the receptors of other hormones or ion channels, which are important for the regulation of the functions of the cardiovascular system. Has no effect on the level of total cholesterol, TG, glucose and uric acid in the blood plasma.

The onset of antihypertensive action of valsartan after its administration inwards in a single dose is observed within 2 hours after administration, the maximum effect is achieved within 4-6 hours.

Indications

Treatment of arterial hypertension.

Treatment of chronic heart failure (IIHA functional class according to NYHA classification) in patients receiving traditional therapy with diuretics, digitalis preparations, as well as with ACE inhibitors or beta-blockers.